Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer

Clinical Breast Cancer

Volumn 13, Issue 1, 2013, Pages 53-60

  Li, Peifeng ^a,b   Liu, Tantan ^a   Wang, Yingmei ^a   Shao, Shuai ^a   Zhang, Weichen ^a   Lv, Yang ^a   Yi, Jun ^a   Wang, Zhe ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Fluorescence in situ hybridization; Her 2 status; Immunohistochemistry

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PIRARUBICIN; RECOMBINANT ENDOSTATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SURGERY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 84872363354     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.09.011     Document Type: Article

References (46)

1. J.Y. Pierga, E. Mouret, V. Laurence Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer The role of clinical response Eur J Cancer 39 2003 1089 1096 (Pubitemid 36555866)
2. N. Wolmark, J. Wang, E. Mamounas Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical Adjuvant Breast and Bowel Project J Natl Cancer Inst Monogr B-18 2001 96 102
3. V. Lorgis, M.P. Algros, C. Villanueva Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour Breast 20 2011 284 287
4. N. Kumaki, S. Umemura, X. Tang Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67 Breast Cancer 18 2011 98 102
5. A. Rody, T. Karn, R. Gätje Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response Breast 16 2007 86 93 (Pubitemid 46172862)
6. G.L. Piper, N.A. Patel, J.A. Patel Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status Am Surg 70 2004 1103 1106
7. R.J. Burcombe, A. Makris, P.I. Richman Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 2005 147 155 (Pubitemid 40188448)
8. E. Sari, G. Guler, M. Hayran Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer Med Oncol 28 2011 57 63
9. H. Neubauer, C. Gall, U. Vogel Changes in tumour biological markers during primary systemic chemotherapy (PST) Anticancer Res 28 2008 1797 1804 (Pubitemid 351892888)
10. T. Hirata, C. Shimizu, K. Yonemori Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer Br J Cancer 101 2009 1529 1536
11. N. Arens, U. Bleyl, R. Hildenbrand HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer Virchows Arch 446 2005 489 496 (Pubitemid 40884281)
12. A.L. Adams, I. Eltoum, H. Krontiras The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma Breast J 14 2008 141 146 (Pubitemid 351341835)
13. S. Taucher, M. Rudas, R.M. Mader Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer Breast Cancer Res Treat 82 2003 207 213 (Pubitemid 37521977)
14. J.J. Li, G.H. Di, L.C. Tang Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil Breast J 17 2011 657 660
15. A.C. Wolff, M.E. Hammond, J.N. Schwartz American Society of Clinical Oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145 (Pubitemid 350003059)
16. K.N. Ogston, I.D. Miller, S. Payne A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 2003 320 327 (Pubitemid 37322062)
17. M. Kurosumi, S. Akashi-Tanaka, F. Akiyama Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) Breast Cancer 15 2008 5 7
18. S. Masood, M.M. Bui Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study Ann Clin Lab Sci 30 2000 259 265 (Pubitemid 30620800)
19. A. Vincent-Salomon, M. Jouve, P. Genin HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2002 2169 2173 (Pubitemid 34411973)
20. R. Simon, A. Nocito, T. Hübscher Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 2001 1141 1146 (Pubitemid 32780965)
21. M. Kasami, T. Uematsu, M. Honda Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy Breast 17 2008 523 527
22. O. Tacca, F. Penault-Llorca, C. Abrial Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy Oncologist 12 2007 636 643 (Pubitemid 47036200)
23. M. Arnedos, A. Nerurkar, P. Osin Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 2009 1948 1952
24. Z. Varga, R. Caduff, B. Pestalozzi Stability of the HER2 gene after primary chemotherapy in advanced breast cancer Virchows Arch 446 2005 136 141 (Pubitemid 40385643)
25. H.J. Burstein, L.N. Harris, R. Gelman Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study J Clin Oncol 21 2003 46 53
26. E.A. Oldham, C. Li, S. Ke Comparison of action of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in human breast cancer cells Int J Oncol 16 2000 125 132
27. L. Sivarajan, K.M. Sivarajan, J. Natarelli Change in HER-2/neu status from negative to positive following treatment in breast cancer: A Case report Case Rep Oncol 4 2011 19 24
28. T. Vu, F.X. Claret Trastuzumab: updated mechanisms of action and resistance in breast cancer Front Oncol 2 2012 62
29. A.L. Wong, S.C. Lee Mechanisms of resistance to trastuzumab and novel Therapeutic strategies in HER2-positive breast cancer Int J Breast Cancer 2012 2012 415170
30. D. Pectasides, A. Gaglia, P. Arapantoni-Dadioti HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy Anticancer Res 26 2006 647 653
31. C. Abrial, I. Van Praagh, R. Delva Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer Oncologist 10 2005 242 249 (Pubitemid 40559589)
32. P. Chollet, S. Charrier, E. Brain Clinical and pathological response to primary chemotherapy in operable breast cancer Eur J Cancer 33 1997 862 866 (Pubitemid 27287036)
33. I.F. Faneyte, J.G. Schrama, J.L. Peterse Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 2003 406 412 (Pubitemid 36308152)
34. M. Kaufmann, G.N. Hortobagyi, A. Goldhirsch Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update J Clin Oncol 24 2006 1940 1949 (Pubitemid 46638994)
35. P. Rastogi, S.J. Anderson, H.D. Bear Preoperative chemotherapy: updates of national surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 2008 778 785 (Pubitemid 351264391)
36. T. Shien, C. Shimizu, K. Seki Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome Breast Cancer Res Treat 113 2009 307 313
37. R.L. Jones, J. Salter, R. A'Hern Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer Breast Cancer Res Treat 119 2010 315 323
38. A. Noske, S. Loibl, S. Darb-Esfahani Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) Breast Cancer Res Treat 126 2011 109 117
39. V. Stearns, B. Singh, T. Tsangaris A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer Clin Cancer Res 9 2003 124 133 (Pubitemid 36109724)
40. E. Arriola, S.M. Rodriguez-Pinilla, M.B. Lambros Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 2007 181 189 (Pubitemid 350045015)
41. L. Yao, Y. Liu, Z. Li HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer Ann Oncol 22 2011 1326 1331
42. T. Shet, A. Agrawal, R. Chinoy Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy-implications for a pathologist Breast J 13 2007 457 464 (Pubitemid 47329332)
43. J. Hannemann, H.M. Oosterkamp, C.A. Bosch Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 23 2005 3331 3342
44. E.A. Mittendorf, Y. Wu, M. Scaltriti Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 2009 7381 7388
45. L. Zhu, L.W. Chow, W.T. Loo Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial Clin Cancer Res 10 2004 4639 4644 (Pubitemid 38955513)
46. J. Hurley, P. Doliny, I. Reis Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 2006 1831 1838 (Pubitemid 46638980)